PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Orforglipron Improves Physical Function More Reliably Than Psychosocial Measures in ATTAIN Trials

orforglipronGLP-1 receptor agonistobesitytype 2 diabetespatient-reported outcomeshealth-related quality of lifeSF-36v2IWQOL-Lite-CTEQ-5D-5LATTAIN-1ATTAIN-2phase 3 randomized trialphysical function Endocrinology / Diabetes / Obesity

Background Information

Orforglipron boosts physical and psychosocial health in obesity.

Orforglipron showed improvements in both physical and psychosocial functioning in adults with obesity, potentially enhancing quality of life. Participants receiving orforglipron had greater improvements in Health-Related Quality of Life (HRQoL) from baseline to week 72 compared to placebo. Phase 3 trials indicate beneficial effects on quality of life with orforglipron, but as a new drug, further research is needed for solid placement in therapy. Orforglipron may improve physical and psychosocial functioning in adults with obesity.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Look M, Bays H, Le Roux CW, Xavier NA, Allen SE, Jouravskaya I, Stefanski A, Dimitriadis GK, Behrend B, Ye W, Li J, Gibble TH, Houle C

Citation: Look M, Bays H, Le Roux CW, et al. Orforglipron improved physical and psychosocial functioning in adults with obesity: Results from ATTAIN phase 3 randomized trials. Obesity pillars. 2026;20:100347. doi:10.1016/j.obpill.2026.100347

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.